New Fixed-Dose Subcutaneous Option for HER2+ Breast Cancer

September 24, 2020
Mark Pegram, MD, Stanford Women's Cancer Center

,
Chau Dang, MD, Memorial Sloan Kettering Westchester

,
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center



x